Context: Patients with multiple endocrine neoplasia type 1 (MEN1) are at high risk of malignant pancreatic neuroendocrine tumors (pNETs). Structural imaging is typically used to screen for pNETs but is suboptimal for stratifying malignant potential. Design: Retrospective observational study.
I mplementation of prospective screening protocols for patients with a MEN1 genotype has shifted morbidity and mortality from midlife complications related to states of hormone excess (hyperparathyroidism-related renal failure and hypergastrinemic peptic ulcer disease) to that of later-onset malignant neuroendocrine tumors (NETs), particularly gastroenteropancreatic NETs (gpNETs), which account for up to half of deaths in patients with MEN1 (1) (2) (3) (4) . Consequently, early identification and management of gpNETs with malignant potential is a key goal in contemporary MEN1 management and surveillance programs (5, 6) .
Clinical practice guidelines for MEN1 management typically recommend anatomical localization of NETs in conjunction with biochemical and hormonal testing (5, 6) . Historically, pancreatic NET (pNET) localization has been performed using computed tomography (CT), ultrasound, and magnetic resonance imaging (MRI), although functional imaging with somatostatin scintigraphy, and more recently [
68 Ga]-DOTA(0)-Tyr(3)-octreotate ( 68 Ga DOTATATE) positron emission tomography (PET)/CT, has also been proposed (7) (8) (9) . However, there is a paucity of studies examining the optimal schedule for functional screening in patients with MEN1; the frequency and modality of screening and the best approach for managing asymptomatic and nonfunctioning pNETs remain to be determined. Similarly, there is a lack of clarity regarding the optimal follow-up and management of nonfunctioning pNETs that are identified at surveillance. Clinical practice guidelines currently suggest surgery for nonfunctioning pNETs of "more than 1 cm in size" and/or pNETs that "have demonstrated significant growth over 6 to 12 months," (3) although some centers reserve surgery for nonfunctioning pNETs .2 cm in size (1, 4, 5) . Tumor markers (e.g., chromogranin A, pancreatic polypeptide, and glucagon) have been also used as an adjunct to imaging; however, these have limited utility in view of their sensitivity of only 33% to 58% for nonfunctioning pNETs (2, 10) .
Histopathological evaluation typically demonstrates multicentric, nonfunctional pNETs of sizes varying from centimetric to microscopic in over 95% of patients with MEN1 (2, 4). The smaller lesions are generally not visualized by conventional anatomical imaging; however, endoscopic ultrasonography (EUS) and functional imaging with 68 Ga DOTATATE PET/CT often disclose pNET disease that is otherwise occult on CT and MRI (2, 3) . Although 68 Ga DOTATATE PET/CT has the ability to image for NETs at multiple anatomic sites, with detectability to 2 to 5 mm in diameter, it does not discern malignant potential (2, 7) . This is particularly problematic in MEN1, in which overdiagnosis of indolent, nonfunctional pNETs exposes patients to the potential for anxiety, excessive testing, and overtreatment (2, 4, 11) .
Studies of FDG PET in the setting of sporadic metastatic NETs have shown a positive correlation between Ki-67 index, histoprognostic grade, and FDG-PET avidity (12) (13) (14) (15) . Moreover, patients with negative FDG-PET scans demonstrate a significantly better overall survival than those with positive FDG-PET scans, regardless of Ki-67 index and histologic classification (4-year survival of 0% for positive FDG PET vs 87% for negative FDG PET) (12, 13, (15) (16) (17) (18) . Additionally, although patients with positive somatostatin receptor scintigraphy have a better prognosis than those with negative somatostatin receptor scintigraphy, this effect was attenuated if concomitant FDG-PET imaging was positive (13) . 18 F-FDG PET/CT has also been shown to be more effective for identifying aggressive (rapidly growing and metastatic) pNETs in circumstances in which 68 Ga DOTATATE PET avidity is absent (7) . Thus, although 18 F-FDG PET/CT is less sensitive than 68 Ga DOTATATE PET/CT and EUS for identifying small and well-differentiated pNETs, 18 F-FDG PET/CT appears more effective than CT, ultrasonography, and MRI for identifying aggressive but well-differentiated neuroendocrine carcinomas with Ki-67 index .10% (8, 19) .
In this study we evaluate the utility of 18 F-FDG PET/ CT imaging for predicting the malignant potential of pNETs in patients with MEN1.
Methods

Patients
All patients with a confirmed MEN1 genotype (Tasman 1 pedigree founder splice-site mutation NM_130799.2:c.446-3, C.G heterozygous) (1, 20) , who underwent 18 F-FDG PET/CT fusion imaging as part of routine MEN1 surveillance at our institution between 1 January 2010 and 30 September 2016, were included in this retrospective study. At our center, we use 18 F-FDG PET/CT for surveillance of patients with MEN1 as well as for follow-up of known pancreatic lesions. Forty-nine patients were identified as eligible, and the clinical records and results of their imaging and pathology studies were reviewed. The research was approved by the Royal Hobart Hospital institutional Human Research Ethics Committee.
Intervention
All patients had a paired noncontrast CT for anatomical localization performed with 18 F-FDG PET, in addition to at least one of the following supplemental imaging modalities: formal CT, ultrasound, or EUS of the abdomen within 12 months of the 18 F-FDG PET study. A majority of patients had serial formal structural imaging studies performed. Comparison was made between the results of 18 F-FDG PET/CT and the results of any other structural imaging performed during the patient's follow up (CT, ultrasound, MRI). When available, surgical histopathology results were also reviewed.
For each patient, the number and avidity of pancreatic lesions detected on 18 F-FDG PET/CT was recorded, as well as compared with other imaging and histology results when available. Data were also recorded for each patient with respect to other MEN1-related pathologies, current age or age at death, and cause of death when relevant, as well as the date of surgery for pNET, if applicable, age at surgery, and duration of follow-up.
A Discovery 690 PET/CT scanner (General Electric Medical Systems) was used to perform 18 F-FDG-PET/CT fusion imaging studies at the Royal Hobart Hospital. Preceding each study, patients fasted for 6 hours. For each patient, a weight-based dose of 18 F-FDG was determined and injected intravenously; 3.7 MBq/kg (minimum, 180 MBq; maximum, 300 MBq) was administered to patients weighing up to 100 kg, and 3 MBq/kg (up to a maximum of 370 MBq) was administered to patients weighing .100 kg (21) . After a period of 60 minutes for 18 F-FDG uptake, positron emission tomography scans were acquired from the vertex to the knees. Noncontrast CT was performed concurrently for anatomical localization and attenuation correction using a 64-slice scanner. CT parameters were set at 120 KeV, 40 to 130 SmartmA (automatic exposure control), and pitch 0.98, reconstructed to 3.7-mm slices to match the PET voxels. Although breath-hold and contrast were not used for the CT studies, the quality was similar to that of standard formal CT imaging studies, apart from the use of thicker slices (3.7 mm vs 1.5 mm for a standard formal CT with contrast) (21) . The total radiation dose was approximately 8 to 15 mSv per FDG-PET study (21, 22) .
Statistical methods
Where appropriate, numerical data are presented as mean 6 standard deviation or median and interquartile range (IQR). Normally distributed variables were analyzed using t test and categorical data by Fisher's exact test. Statistical analysis was performed using GraphPad Prism7.
Results
Forty-nine patients with MEN1 underwent 18 F-FDG PET scans. The mean age was 45.2 6 14.3 years; 34 (69.4%) of the patients were women. Eight patients exhibited FDG-avid gastroenteropancreatic (hepatic or pancreatic) disease. Of these eight patients, six (75%) patients had FDG uptake and pancreatic disease, four (50%) patients had isolated pNET-avid disease (three with concomitant structural lesions on anatomic imaging, and one with only a small pancreatic focus of isolated FDG avidity, with no structural imaging correlate), and two (25%) patients had synchronous pNET and hepatic FDG-avid lesions. The remaining two (25%) patients had isolated FDG-avid liver metastases ( Fig. 1 ; Table 1 ). Across all structural diagnostic imaging modalities, 25 of the 49 patients studied (51.0%) had structural evidence of one or more pNETs (mean age, 44.3 6 13.4 years; 60% female) with a mean lesion size of 17.4 6 12.7 mm (median, 15 mm; IQR, 8 to 21.5 mm). Compared with other available imaging modalities, FDG PET/CT detected pNETs in eight (66.7%) of 12 patients with contrast CT-evident lesions .10 mm in diameter, and in eight (88.9%) of nine patients with contrast CT-evident lesions .15 mm in diameter. Conversely, FDG PET/CT identified pNET lesions in three patients not identified with pNETs by contrast CT. Combined with transabdominal ultrasound, FDG PET/CT identified all patients with lesions detected by contrast CT plus lesions in an additional four patients in whom contrast CT had failed to identify pNETs (Tables 2 and 3) .
Surgical resection of pancreatic lesions was undertaken in eight (32.0%) patients with pNETs, seven of whom had Ki-67 evaluated. The Ki-67 was positively associated with FDG avidity (Table 4 ; Fig. 2 ). In three patients, the Ki-67 was $5% (Ki-67, 20%, 10%, and 5% for lesions of 62 mm, 24 mm, and 22 mm, respectively). Furthermore, all patients with Ki-67 $5% had FDG-avid results on 18 F-FDG PET/CT preoperatively. Of the remaining four patients, the Ki-67 index ,2%, and preoperative FDG imaging was nonavid (Fig. 2) . None of the patients lacking FDG-avid pNETs on their index FDG imaging subsequently developed evidence of pNET size progression or pNET metastases over a mean follow-up of 23.7 months (median, 15.5 months; IQR, 6.3 to 41.2 months).
In summary, 75% of the eight patients with evidence of intraabdominal FDG avidity had evidence of either aggressive (Ki-67, $5%) or metastatic gpNETs compared with one of 41 patients (2.4%) without evidence of FDGavid gpNETs (P , 0.001). The sensitivity and specificity of 
Discussion
Prior studies reporting on the utility of FDG PET for gpNET evaluation have been in the context of sporadic disease and have not explicitly addressed the context of MEN1 (13, 23) . Typically, these studies have focused on patients with advanced gpNETs. The current study specifically evaluates 18 F-FDG PET/CT for identification and risk stratification of pNETs in the setting of MEN1 and shows that 18 F-FDG PET/CT is an effective screening tool for both identification and risk stratification of clinically relevant pNETs. Although, traditionally, pNETs (functional or otherwise) have been detected in 30% to 80% of patients with MEN1, with improving detection methods this has increased to .80% (3). Histopathological studies demonstrate 95% to 100% of patients with MEN1 have nonfunctional pNETs; the lesions are typically multiple, with sizes varying from centimetric to microscopic (2, 3) . Recent studies that have used increasingly sensitive modalities such as EUS and 68 Ga DOTATATE PET/CT have identified prevalent yet asymptomatic pNETs in most patients with MEN1 (2-4, 24) . Pancreatic EUS and 68 Ga DOTATATE PET/CT, although particularly useful as adjuncts to structural imaging with transabdominal ultrasonography for the identification of otherwise undisclosed pNETs (often much smaller than 2 cm) that require surgical resection as a result of functional syndromes such as insulinoma, do increase the likelihood of pNET overdiagnosis (2-4, 24). Our results similarly show that the capacity to detect pNETs is increased with the use of highly sensitive modalities; however, the clinical merit of detecting subcentimetric, nonfunctioning, asymptomatic, and FDGnegative lesions is doubtful. There is risk of causing harm to patients by overtreatment of these mostly benign lesions, given that most (.80%) of pNETs ,2 cm do not increase in size, and only a minority appear to harbor malignancy (4). Pancreatic NETs also have a lower rate of lymph nodal metastasis compared with, for example, duodenal gastrinomas (10% to 33% vs 34% to 85% at diagnosis), and the presence of lymph nodal metastasis would appear to have much less prognostic weight than the presence of hepatic metastases (3, 4). Interestingly Binderup et al. (18) found that there was no difference in the mortality rate between patients with CT-identified liver metastases and those without. Some studies have shown that patients with MEN1 with nonfunctioning pNETs ,2 cm have no increased mortality (2, 3) ; therefore, the benefit of identifying very small pNETs is questionable in the absence of hormone-excess states. Our findings confirm that FDG avidity in MEN1 is effective for identifying pNETs that require resection (Ki-67 $5% and/or metastatic potential). Consequently, the challenge of surveillance and clinical management of patients with MEN1 is not to identify every pNET, but to identify those lesions that, if left untreated, will increase morbidity and mortality. 18 F-FDG PET/CT has been proposed as a modality that may assist in the assessment of patients and management decisions, including the need for surgery (4) . Some studies (13) (14) (15) 18) have examined the performance of FDG PET and somatostatin receptor scintigraphy in the setting of metastatic NETs, although not specifically in patients with MEN1. FDG-PET avidity was positively correlated with Ki-67 index and histoprognostic grade, whereas somatostatin receptor scintigraphy was not, and FDG PET had better prognostic utility (12, 13, (15) (16) (17) (18) 25) . Patients with a negative FDG PET had a significantly better overall survival than those with a positive FDG PET, regardless of Ki-67 index, histologic classification, or the result of somatostatin receptor scintigraphy (4-year survival of 0% for positive FDG PET vs 87% for negative FDG PET; hazard ratio of 10 for death in cases of FDG-PET positivity) (13, 15) . Those with positive somatostatin receptor scintigraphy had a better prognosis than those with negative somatostatin receptor scintigraphy (13) .
Not all pNETs with a high Ki-67 are poorly differentiated, and this is reflected by the fact that patients with grade 3 pNETs have similar survival compared with patients with grade 2 pNETs. Furthermore, a number of recent studies have shown that even in the setting of low Ki-67 index (,2%), FDG-PET positivity correlates with poor prognosis (13, 14, 18) , and in some recent studies, FDG-PET positivity has been reported to have a stronger prognostic value than Ki-67 (18) . Additionally, grading of pNETs does not currently account for FDG-avidity status, and somatostatin receptor expression does not necessarily translate to negative FDG-PET status, within or between lesions (12, 16, 25) . This indicates that mixed neoplastic cellular phenotypes ranging from poorly differentiated to well-differentiated populations coexist within individual tumors (13, 18, 26) . Consequently, it has been suggested that the high prognostic value of FDG PET overrides the lower diagnostic sensitivity of the CT component of the FDG-PET protocol compared with some other structural and functional imaging modalities (18) .
The combination of 18 F-FDG PET/CT and 68 Ga DOTATATE PET may therefore be useful, given that the two modalities provide different but complementary information, and there may be a mixed population of cellular receptor expression both within and between lesions in the same patient (16, 18, 27) . However, using 68 Ga DOTATATE PET for primary screening is likely to lead to overdiagnosis of benign and nonfunctioning pNETs, resulting in unnecessary anxiety for patients. Avidity on 68 Ga DOTATATE PET should therefore not be used as the single indication for surgery; rather, we suggest using 68 Ga DOTATATE PET as a staging approach in order to guide the decision to perform surgery vs other treatments, such as initiation of therapy with somatostatin analogs (e.g., octreotide, lanreotide) as tumor-suppression agents in lieu of surgery (4, 18, (28) (29) (30) . Somatostatin analogs, over the course of 12 to 75 months of therapy, have been shown to produce tumor response in 10% and to maintain stable disease in 80% of patients with MEN1 who have pNETs .2 cm (4, 30) . Candidates for this therapy as opposed to surgery might, for example, be those with multiple small (#2 cm), nonfunctioning pNETs, without rapid growth, with no FDG-avid lesions.
Our data suggest that adding 18 F-FDG PET/CT to the assessment of nonfunctioning pNETs in patients with MEN1 is useful and provides a combination of not only anatomical information regarding the size and location of pNETs, via the CT component of the study, but also information on malignancy risk on the basis of the FDGavid status. Given that 18 F-FDG PET/CT is less sensitive that other modalities such as 68 Ga DOTATATE PET and EUS for detecting very small lesions (e.g., ,0.5 cm), there is less risk of overdiagnosis and overtreatment of very small, nonfunctioning pNETs, which are usually benign, and as mentioned, are almost ubiquitous on histopathologic studies, whereas 18 F-FDG PET/CT offers adequate sensitivity for the detection of lesions of clinically relevant size. We propose that for detecting and monitoring nonfunctioning, incidental pNETs in MEN1, FDG PET/CT Aside from reducing overdiagnosis-and overtreatment-related morbidity, this protocol limits the radiation exposure of patients who require a lifetime of surveillance. The effective whole-body radiation exposure from the FDG PET/CT protocol is approximately 8 to 15 mSv for each study, compared with conventional contrast CT that involves 8 mSv for radiation of the chest, 10 mSv for radiation of the abdomen, and 10 mSv for radiation of the pelvis (21, 22, 31, 32) . Models predicting cancer risk from ionizing radiation estimate that the lifetime risk from exposure to 5 mSv is, on average, 1 in 4000 for provoking a fatal cancer, and for 20 mSv is 1 in 1000, with the risk of cancer decreasing in those over 40 years of age at the time of exposure, but substantially higher for children and young adults exposed to ionizing radiation (31, 32) .
Limitations
This study was based on a retrospective medical records review. Factors such as multiple test modalities and clinically driven investigation, rather than the use of a prespecified protocol, require caution in interpretation of findings. The small number of patients, particularly those with available histology, also limits the power of the study. Similarly, we did not attempt to conduct a pNET prevalence study; therefore, more comprehensive, highly sensitive imaging with EUS and 68 Ga DOTATATE would likely disclose a greater pNET prevalence than we report, albeit lesions that are subcentimetric, clinically and biochemically occult, and of uncertain relevance.
Conclusion
Our findings suggest that 18 F-FDG PET/CT is a useful screening modality for patients with MEN1 who have pNETs of greater malignant potential. Given the correlation between Ki-67 index and FDG avidity, as well as the increased association between Ki-67 and nodal metastases, surgical resection is recommended for all FDG-avid pNETs, regardless of size. For non-FDG-avid pNETs, size criteria should be combined with growth trajectory and other clinical features when deciding upon management directions.
Further studies that include larger data sets are required to confirm these findings; however, use of 18 F-FDG PET/CT has the potential to minimize surgical procedures (and unnecessary treatment or overtreatment) for benign (low grade) pNETs in patients with MEN1, and to provide prognostic value for lesions ;20 mm in size that may or may not be low grade.
